Malignant Fibrous Histiocytoma Global Clinical Trials Review, H2, 2016

Malignant Fibrous Histiocytoma Global Clinical Trials Review, H2, 2016


  • Products Id :- GDHC3722CTIDB
  • |
  • Pages: 73
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Malignant Fibrous Histiocytoma Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, "Malignant Fibrous Histiocytoma Global Clinical Trials Review, H2, 2016" provides an overview of Malignant Fibrous Histiocytoma clinical trials scenario. This report provides top line data relating to the clinical trials on Malignant Fibrous Histiocytoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9

Top Five Countries Contributing to Clinical Trials in Europe 10

Top Countries Contributing to Clinical Trials in North America 11

Top Countries Contributing to Clinical Trials in Middle East and Africa 12

Clinical Trials by G7 Countries: Proportion of Malignant Fibrous Histiocytoma to Oncology Clinical Trials 13

Clinical Trials by Phase in G7 Countries 14

Clinical Trials in G7 Countries by Trial Status 15

Clinical Trials by E7 Countries: Proportion of Malignant Fibrous Histiocytoma to Oncology Clinical Trials 16

Clinical Trials by Phase in E7 Countries 17

Clinical Trials in E7 Countries by Trial Status 18

Clinical Trials by Phase 19

In Progress Trials by Phase 20

Clinical Trials by Trial Status 21

Clinical Trials by End Point Status 22

Subjects Recruited Over a Period of Time 23

Clinical Trials by Sponsor Type 24

Prominent Sponsors 25

Top Companies Participating in Malignant Fibrous Histiocytoma Therapeutics Clinical Trials 26

Prominent Drugs 28

Clinical Trial Profile Snapshots 29

Appendix 70

Abbreviations 70

Definitions 70

Research Methodology 71

Secondary Research 71

About GlobalData 72

Contact Us 72

Disclaimer 72

Source 73

List of Figures

Malignant Fibrous Histiocytoma Therapeutics, Global, Clinical Trials by Region (%), 2016* 6

Malignant Fibrous Histiocytoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7

Malignant Fibrous Histiocytoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8

Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9

Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10

Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11

Proportion of Malignant Fibrous Histiocytoma to Oncology Clinical Trials, G7 Countries (%), 2016* 13

Malignant Fibrous Histiocytoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 14

Malignant Fibrous Histiocytoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 15

Proportion of Malignant Fibrous Histiocytoma to Oncology Clinical Trials, E7 Countries (%), 2016* 16

Malignant Fibrous Histiocytoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 17

Malignant Fibrous Histiocytoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 18

Malignant Fibrous Histiocytoma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 19

Malignant Fibrous Histiocytoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 20

Malignant Fibrous Histiocytoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 21

Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 22

Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 23

Malignant Fibrous Histiocytoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 24

Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 25

Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 26

Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

GlobalData Methodology 71

List of Tables

Malignant Fibrous Histiocytoma Therapeutics, Global, Clinical Trials by Region, 2016* 6

Malignant Fibrous Histiocytoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7

Malignant Fibrous Histiocytoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8

Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9

Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10

Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, North America, Top Countries, 2016* 11

Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12

Proportion of Malignant Fibrous Histiocytoma to Oncology Clinical Trials, G7 Countries (%), 2016* 13

Malignant Fibrous Histiocytoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 14

Malignant Fibrous Histiocytoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 15

Proportion of Malignant Fibrous Histiocytoma to Oncology Clinical Trials, E7 Countries (%), 2016* 16

Malignant Fibrous Histiocytoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 17

Malignant Fibrous Histiocytoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 18

Malignant Fibrous Histiocytoma Therapeutics, Global, Clinical Trials by Phase, 2016* 19

Malignant Fibrous Histiocytoma Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 20

Malignant Fibrous Histiocytoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 21

Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 22

Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 23

Malignant Fibrous Histiocytoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 24

Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 25

Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27

Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

F. Hoffmann-La Roche Ltd.

Daiichi Sankyo Company, Limited

Threshold Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited

Quintiles Transnational Holdings Inc.

Novartis AG

Merck & Co., Inc.

GlaxoSmithKline Plc

Children's Cancer and Leukaemia Group

AstraZeneca Plc

select a license

Single User License
USD 2500 INR 165525
Site License
USD 5000 INR 331050
Corporate User License
USD 7500 INR 496575

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com